This isn't surprising. Now that its acquistion of Wyeth is complete, the big drugmaker will "significantly reduce" R&D in various locations, and an undisclosed number of jobs will be gone (here's thepress release).
Various functions will be moved from Collegeville, Pa; Pearl River, NY; and St. Louis to other locations. Meanwhile, operations will no longer take place in Princeton, NJ; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK. Pfizer will also consolidate R&D functions from its New London, Ct., site to its nearby research facility in Groton, Ct. As a result of these changes, Pfizer will reduce its global R&D square footage by 35 percent.
R&D activities will now be conducted at five main sites and nine specialized units around the world as compared with 20 R&D sites at the time the Wyeth deal closed on Oct. 16 (here's a list of what work is done where). Research sites that will serve as central hubs are located in Cambridge, Ma; Groton, Ct; Pearl River, NY; La Jolla, Ca; and Sandwich, UK. R&D work also continues in San Francisco, Cambridge, UK, and Shanghai, China.
In its recent quarterly SEC filing, Pfizer noted that it plans to reduce its workforce by 30,900 employees, mostly in manufacturing, sales and research, and, so far, about 26,300 jobs have already been eliminated (see page 9).